OVID

Ovid Therapeutics Inc. (OVID) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, specifically targeting seizures and neuropsychiatric conditions. The company operates as a single reporting segment and is classified as a smaller reporting company. As of June 30, 2026, the company had 184,755,735 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped significantly from $6.4 million to $0.7 million. The prior period included a $7.0 million one-time payment from an amendment to the Marinus License Agreement, which was not repeated in the current period.
• Increased Operating Expenses: Total operating expenses rose by $10.3 million (43% increase). Research and Development (R&D) expenses increased by $8.0 million, driven by clinical and preclinical activities for lead programs OV329 and OV4071. General and Administrative (G&A) expenses increased by $2.2 million, primarily due to higher legal and professional fees.
• Capital Raising: The company significantly bolstered its liquidity through financing activities. In the first half of 2026, it raised approximately $110.6 million in net cash from financing, including a March 2026 private placement ($56.2 million net), the exercise of Series A warrants ($51.8 million net), and ATM program sales ($2.4 million net).
• Investment Portfolio: Marketable securities increased from $77.3 million at year-end 2025 to $158.4 million at June 30, 2026, reflecting the deployment of recent capital raises.

Guidance, Outlook, and Risks

• Liquidity Runway: Management believes current cash, cash equivalents, and marketable securities ($169.8 million) are sufficient to fund operations for at least the next 12 months from the filing date.
• Pipeline Progress: The company is advancing OV329 and OV4071. In May 2026, Ovid entered into an agreement with a newly formed private company ("NewCo") to assign intellectual property rights related to soticlestat, receiving Series Seed Shares valued at $0.7 million as upfront revenue.
• Future Funding Needs: The company expects to incur substantial operating losses for the foreseeable future and will require additional capital to fund clinical trials and commercialization efforts. Future funding may come from equity offerings, debt, or collaborations.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional financing, potential dilution from future equity issuances, and reliance on third-party manufacturers and CROs. The company also faces risks related to the failure of previous programs (e.g., soticlestat discontinuation by Takeda) and macroeconomic factors affecting capital markets.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $31.5 million operating cash burn over six months against the $169.8 million cash balance to confirm the 12-month runway assertion.
• Revenue Recurrence: Confirm the non-recurring nature of the $7.0 million Marinus payment in 2025 and assess the likelihood of future licensing revenue given the current pipeline status.
• Financing Terms: Review the terms of the outstanding Series B Warrants (28.9 million shares) and the remaining capacity under the ATM program ($64.3 million as of July 2026) to understand potential future dilution.
• Program Milestones: Monitor the clinical progress of OV329 and OV4071, as these are the primary drivers of the increased R&D spend and future valuation.
• Equity Investments: Review the valuation methodology for long-term equity investments (Gensaic, Graviton, NewCo) totaling $42.7 million, which are subject to fair value adjustments.